A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus
Status:
Unknown status
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The study hypotheses to be tested in this study are:
- Conversion to everolimus at 3 months post-transplantation is safe and effective;
- Accurate noninvasive molecular diagnostic tests can replace biopsy at 3 months
pre-conversion (for the diagnosis of subclinical cellular and/or humoral rejection,
tissue fibrosis and calcineurin inhibitor-induced nephrotoxicity) in kidney transplant
recipients;
- Follow-up biopsy at 12 months post-conversion (for the diagnosis of tissue fibrosis) can
be replaced with accurate noninvasive molecular diagnostic tests in kidney transplant
recipients.